Benefits of Trimetazidine in MASLD Patients (MASLD)
Evaluation of Potential Benefits of Trimetazidine in the Management of Patients With Metabolic Associated Steatotic Liver Disease (MASLD)
Sponsor: October 6 University
A PHASE2 clinical study on Metabolic Associated Fatty Liver Disease, this trial is completed. The trial is conducted by October 6 University and has accumulated 6 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Completed PHASE2
-
May 2025 — Jul 2025 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- October 6 University
For direct contact, visit the study record on ClinicalTrials.gov .